Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jack

Showing results (391-400 of 594) with videos related to

Pageof 60
Sort By:
Molecular Cancer Therapeutics|March 22, 2013
Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal diseaseLai-Ping Zhong, Dong-Wang Zhu, William N William, et al.
Lung Cancer (Amsterdam, Netherlands)|September 21, 2020
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancerXiaoke Liu, Lingzhi Hong, Monique Nilsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2014
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapyErick Riquelme, Milind Suraokar, Carmen Behrens, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2012
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapyApar Pataer, Neda Kalhor, Arlene M Correa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2013
Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapyKathryn A Gold, Edward S Kim, Diane D Liu, et al.
Frontiers in Oncology|April 9, 2024
Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma featuresHui Li, Xin Hu, Matthew S Ning, et al.
Patterns (New York, N.Y.)|August 21, 2023
SwarmDeepSurv: swarm intelligence advances deep survival network for prognostic radiomics signatures in four solid cancersQasem Al-Tashi, Maliazurina B Saad, Ajay Sheshadri, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 28, 2010
Biological activity of celecoxib in the bronchial epithelium of current and former smokersEdward S Kim, Waun K Hong, J Jack Lee, et al.
The Oncologist|July 2, 2020
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaCarl M Gay, Yanhong Zhou, J Jack Lee, et al.
BMJ Open|November 25, 2025
Stiefel MD Anderson OroPharynx cancer (MDA-OPC) cohort: a single-institution, prospective longitudinal outcomes studyAmy Moreno, Ariana J Sahli, Faye Johnson, et al.
Pageof 60

Showing results (391-400 of 594) with videos related to

Sort By:
Pageof 60
Molecular Cancer Therapeutics|March 22, 2013
Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal diseaseLai-Ping Zhong, Dong-Wang Zhu, William N William, et al.
Lung Cancer (Amsterdam, Netherlands)|September 21, 2020
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancerXiaoke Liu, Lingzhi Hong, Monique Nilsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2014
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapyErick Riquelme, Milind Suraokar, Carmen Behrens, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2012
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapyApar Pataer, Neda Kalhor, Arlene M Correa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 25, 2013
Prediction of survival in resected non-small cell lung cancer using a protein expression-based risk model: implications for personalized chemoprevention and therapyKathryn A Gold, Edward S Kim, Diane D Liu, et al.
Frontiers in Oncology|April 9, 2024
Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma featuresHui Li, Xin Hu, Matthew S Ning, et al.
Patterns (New York, N.Y.)|August 21, 2023
SwarmDeepSurv: swarm intelligence advances deep survival network for prognostic radiomics signatures in four solid cancersQasem Al-Tashi, Maliazurina B Saad, Ajay Sheshadri, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 28, 2010
Biological activity of celecoxib in the bronchial epithelium of current and former smokersEdward S Kim, Waun K Hong, J Jack Lee, et al.
The Oncologist|July 2, 2020
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaCarl M Gay, Yanhong Zhou, J Jack Lee, et al.
BMJ Open|November 25, 2025
Stiefel MD Anderson OroPharynx cancer (MDA-OPC) cohort: a single-institution, prospective longitudinal outcomes studyAmy Moreno, Ariana J Sahli, Faye Johnson, et al.
Pageof 60